Vital Therapies shares dive as liver system fails trial

U.S. biotech firm Vital Therapies Inc said it will explore strategic options after its liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent on Wednesday.

from Reuters: Health https://ift.tt/2CKXY3i